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The medical importance of the human microbiome
The human intestine carries a vast and diverse microbial 
ecosystem that has co-evolved with our species and is 
essential for human health [1,2]. Mammals possess an 
‘extended genome’ of millions of microbial genes located 
in the intestine: the microbiome [3]. This multigenomic 
symbiosis is expressed at the proteomic and metabolic 
levels in the host and it has therefore been proposed that 
humans represent a vastly complex biological ‘super-
organism’ in which part of the responsibility for host 
meta bolic regulation is devolved to the microbial sym-
bionts [4]. Modern interpretation of the gut microbiome 
is based on a culture-independent, molecular view of the 
intestine provided by high-throughput genomic screen-
ing technologies [5,6]. Also, the gut microbiome has been 
directly implicated in the etiopathogenesis of a number 
of pathological states as diverse as obesity [7], circulatory 
disease [8], inflammatory bowel diseases (IBDs) [9] and 
autism [10] (Figure 1). The gut microbiota also influence 
drug metabolism and toxicity [11], dietary calorific bio-
availability [12], immune system conditioning and res-
ponse [13], and post-surgical recovery [14]. The implica-
tion is that quantitative analysis of the gut microbiome 
and its activities is essential for the generation of future 
personalized healthcare strategies [15] and that the gut 
microbiome represents a fertile ground for the develop-
ment of the next generation of therapeutic drug targets. 
It also implies that the gut microbiome may be directly 
modulated for the benefit of the host organism.
The gut microbiota therefore perform a large number 
of important roles that define the physiology of the host, 
such as immune system maturation [16], the intestinal 
response to epithelial cell injury [17], and xenobiotic [18] 
and energy metabolism [7]. In most mammals, the gut 
microbiome is dominated by four bacterial phyla that 
perform these tasks: Firmicutes, Bacteroidetes, Actino-
bacteria and Proteobacteria [19]. The phylotype composi-
tion can be specific and stable in an individual [20], and 
in a 2-year interval an individual conserves over 60% of 
phylotypes of the gut microbiome [21]. This implies that 
each host has a unique biological relationship with its gut 
microbiota [22,23], and by definition that this influences 
an individual’s risk of disease. The gut microbiome varies 
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between species and, as a result, in vivo models utilizing 
gnotobiotic rodents or pigs conventionalized with human 
baby flora (HBF) have been adopted to permit more 
accurate modeling of the human gut [24]. Future 
experimental models must also accurately replicate the 
metabolic function of the gut microbiome [25]. For this 
to occur, the ‘healthy’ intestinal microbiome must first be 
understood; for example, differences between individuals 
are known to be more marked among infants than in 
adults [26], but later in life the gut microbiome converges 
to more similar phyla. It is not yet known how such an 
important symbiotic relationship, even in apparently well 
neonates, influences long-term health outcome. There-
fore, there is now a significant effort to define a ‘core’ 
micro biome to determine the role played by the gut 
micro biome in diseases across geographically diverse 
populations [6]. Here, we review recent studies that have 
provided important insights into the human gut micro-
biome, and the functional role of the gut microbiome in 
health, disease and in drug efficacy. We review current 
methods for the modulation of the gut microbiome for 
the improvement of human health and disease, and 
Figure 1. Diseases influenced by gut microbial metabolism. The variety of systemic diseases that are directly influenced by gut microbial 
metabolism and its influence on other mammalian pathways, such as the innate immune system, are shown. Specifically highlighted are the 
metabolic pathways involved in drug metabolism and obesity that are directly influenced by the gut microbial content. Ags, antigens; C. bolteae, 
Clostridium bolteae; DCs; dendritic cells; SCFA, short-chain fatty acid; TLR, Toll-like receptor.
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assess the translational and therapeutic implications of 
this rapidly evolving area of research.
Recent insights into gut microbiome variation and 
activity
The advent of 16S rRNA gene-sequence-based methods 
[27] has led to the description of the substantial diversity 
of the gut microbiome between healthy individuals 
[28-30]. It has also led to new insights into the presence 
of particular species and strains in the human gut and 
their variance between intestinal locations and species of 
mammal. For example, 16S RNA approaches have been 
used to study the maturation of murine cecal microbiota, 
and they have demonstrated the existence of a large 
number of yet unidentified bacteria that inhabit it [31]. 
Such ‘culture-independent’ techniques are used to 
measure the stability of the microbiome over time and its 
stability when transferred between species. This is essen-
tial for building robust experimental models for the human 
microbiome and for delineating important mecha nistic 
processes in the development of human disease states. 
Genomic strategies, such as denaturing gradient gel 
electrophoresis (DGGE) of 16S rRNA sequences, have 
commonly been employed for this purpose. Analysis of 
human microbiota-associated (HMA) rat feces using this 
approach has revealed that the Bacteroides/Prevotella 
and Faecalibacterium species are dominant in both 
humans and HMA rats post-transfection [32]. However, 
HMA rats also possessed Ruminococcus, which was not 
present in the human DGGE profile. With this exception, 
the sequences originating from both rats and human 
samples were represented in all major branches of a non-
parametric statistical method for computational phylo-
genetics known as a maximum parsimony tree. Analysis 
of 16S rRNA analysis has also provided new insights into 
the Cytophaga-Flavobacterium-Bacteroides phylum, 
which has recently been found to be common to the 
intestines of mice, rats and humans [33].
Recent advances in sequencing technologies have led to 
the wider use of metagenomic analysis for studying 
complex ecosystems such as the human gut [34-36], and 
some key findings from human studies are outlined in 
Table 1. This approach functions on the principle that the 
genome sequences of abundant species will be well repre-
sented in a set of random shotgun reads, whereas species 
with lower abundance may be represented by a small 
number of sequences, thus permitting the comprehensive 
measurement of the response of an ecosystem to an 
environmental perturbation or therapeutic intervention. 
This technology brings with it the significant challenge of 
managing vast data sets. For example, in three separate 
studies 3 Gb of microbial sequences were generated from 
fecal samples of only 33 individuals from the USA or 
Japan [2,29,37]. Advances in analytical approaches are 
only exacerbating this problem and in a separate analysis 
576.7 Gb of sequence, almost 200 times more than in all 
previous studies, was generated using an IlluminaTM 
Genome Analyzer (Illumina, San Diego, CA, USA) for 
deep sequencing of total DNA from fecal samples of 124 
European adults (Table 1).
However, metagenomic sequencing of the gut micro-
biome has some limitations. The intestinal epithelium is 
composed of three functional barriers: a physical barrier, 
an innate immune barrier and an adaptive immune 
barrier [38]. The relationship between commensal gut 
flora and the intestinal barrier is complex, and occurs at 
each of these interfaces, and fecal metagenomics does 
not therefore measure ecosystem changes at all levels. 
Also, metagenomic analysis of fecal samples does not 
provide a comprehensive picture of important molecular 
interactions within the complex topography and niches 
in the gut. Nonetheless, metagenomic analysis does 
permit some inference of functional information. Gill et 
al. [2] reported the variation between two individuals in 
the distal gut metagenome. The authors described 
statistically significant variability in the enrichment of 
several classes of genes involved in energy metabolism, 
carbohydrate, amino acid and nucleotide transport and 
co-enzyme transport. Clusters of orthologous groups 
analysis also revealed the under-representation of genes 
involved in secondary metabolite biosynthesis, and 
inorganic ion transport and metabolism in the human 
distal gut microbiome (Table 1). This suggested that there 
is significant interindividual and interspecies variability.
The key aim of the majority of this work has therefore 
been to try and define a ‘core microbiome’. This is an 
important aim, as it implies that we all share a key 
number of essential species or strains that help to define 
human health and, more importantly, that can then be 
mined for drug targets. Data from these studies have 
been conflicting on this point. Turnbaugh et al. [39] 
recently concluded that a core microbiome based on 
species or strain data may not be present, because their 
data demonstrated that by adulthood no single bacterial 
phylotype was detectable at an abundant frequency in the 
guts of all 154 humans sampled in their metagenome 
wide study. Qin et al. [6] reported the definition of the 
minimal core microbiome: 576.7 Gb were sequenced 
from 124 individuals, and this demonstrated that 18 
species were found in all individuals; 57 species were 
demonstrated in ≥90% of the study cohort, and 75 species 
were found in ≥50% of the study cohort. However, this 
may reflect a different analytical approach, and this study 
also employed a cohort of patients with IBD. Therefore, it 
may be that the gut pathology aligns the gut microbiota, 
and reduces the variability found in a healthier populace. 
Turnbaugh et al. have argued that a core microbiome 
may exist at a functional level (for example at a genomic, 
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Table 1. Human metagenomic studies that have studied the distal gut microbiome
Study
Number of 
humans
Sequencing 
technology Sequence length Phylogenetic data and key findings
Gene function (for example, KEGG/COG-
enriched processes) 
Gill et al. 
(2006) [2]
2 (1 male, 
1 female, 
healthy)
ABI 3730xl 
sequencer 
(Applied 
Biosystems)
17,668 contigs; 
14,572 scaffolds; 
33,753,108 bp; 
50,164 ORFs; 
19,866 unique 
database matches 
predicted
72 bacterial phylotypes identified; 1 
archaeal phylotype (Methanobrevibacter 
smithii); 16 novel bacterial phylotypes.
Phylotypes assigned: Firmicutes (62 
phylotypes, 105 sequences) and the 
Actinobacteria (10 phylotypes, 27 
sequences)
Energy production and conversion; carbohydrate 
transport and metabolism; amino acid transport 
and metabolism; coenzyme transport and 
metabolism; secondary metabolites biosynthesis, 
and transport and catabolism; MEP pathway for 
biosynthesis of DXP and IPP; β-glucuronidase 
activity induced
Kurokawa 
et al. (2007) 
[37]
7 adults, 
2 children 
and 4 
unweaned 
infants 
(Japanese 
and 
Japanese 
American)
ABI 3730 
sequencers 
(Applied 
Biosystems) 
or the ET 
chemistry on 
MegaBACE4500 
sequencers (GE 
Healthcare)
1,057,481 shotgun 
reads representing 
sequences of 727 
Mb; total length 
of the contigs 
and singletons 
from 13 samples 
was 478.8 Mb; 
identified 20,063 
to 67,740 potential 
protein-encoding 
genes
17% to 43% of predicted genes 
assigned to particular genera (35 to 65 
genera, 121 in total). 
Adults and weaned children: 
Bacteroides and genera belonging 
to division Firmicutes (for example, 
Eubacterium, Ruminococcus 
and Clostridium, and the genus 
Bifidobacterium. Infants: Bifidobacterium 
and/or a few genera from the family 
Enterobacteriaceae, such as Escherichia, 
Raoultella and Klebsiella
Carbohydrate transport and metabolism; 
under-representation of those for ‘lipid transport 
and metabolism’; defense mechanisms; cell 
motility, secondary metabolites biosynthesis, 
transport and catabolism and post-translational 
modification and protein turnover; pyruvate-
formate lyase enriched; formate hydrogenlyase 
system under-represented 
Turnbaugh 
et al. 2009 
[39,100]
154 (31 
MZ and 23 
DZ female 
twin pairs 
and their 
mothers 
n = 46, 
twins 
concordant 
for obesity 
or leanness)
454 
Pyrosequencing
9,920 near 
full-length and 
1,937,461 partial 
bacterial 16S rRNA 
sequences
Gut microbiome shared among family 
members; degree of co-variation 
between adult MZ and DZ twin pairs; 
no single abundant bacterial species 
shared by all 154 individuals; wide array 
of shared microbial genes in sampled 
general population: ‘core microbiome’ 
at the gene level. 
Lower proportion of Bacteroidetes and 
a higher proportion of Actinobacteria 
in obese subjects and reduced bacterial 
diversity. Altered representation 
of bacterial genes and metabolic 
pathways, including those involved in 
nutrient harvest
Total of 156 total CAZy families found within at 
least one human gut microbiome: 77 glycoside 
hydrolase, 21 carbohydrate-binding module, 35 
glycosyltransferase, 12 polysaccharide lyase, 11 
carbohydrate-esterase families. Carbohydrate 
metabolism pathways enriched in Bacteroidetes 
bins; transport systems in Firmicutes bins; 
transcription and translation pathways enriched; 
carbohydrate and amino acid metabolism; 
secretion systems, and membrane transport for 
import of nutrients, including sugars varied in 
their enrichment
Qin et al. 
(2010) [6]
124 healthy, 
overweight 
and obese 
individual 
human 
adults; 21 
ulcerative 
colitis, 4 
Crohn’s 
disease
Illumina GA 6.58 million 
contigs (>500 
bp giving a total 
contig length of 
10.3 Gb); 576.7 Gb
Definition of minimal core microbiome: 
at 1% (40 kb) coverage, 18 species 
in all individuals, 57 in ≥90% and 75 
in ≥50% of individuals; 99.96% of 
the phylogenetically assigned genes 
belonged to the bacteria and archaea. 
Bacteroidetes and Firmicutes had the 
highest abundance. 
Network analysis of 155 species 
in at least one individual at ≥1% 
coverage had prominent clusters for 
Bacteroidetes, Dorea/Eubacterium/
Ruminococcus, Bifidobacteria, 
Proteobacteria and streptococci/
lactobacilli groups
Genes related to adhesion and harvesting sugars 
of the globoseries glycolipids; phage-related 
proteins; biodegradation of complex sugars and 
glycans, for example, pectin (and its monomer, 
rhamnose) and sorbitol; three-quarters of 
prevalent gut functionalities from novel gene 
families; approximately 45% of functions present 
in <10% of the sequenced bacterial genomes
Koenig et al. 
[101]
1 infant 
over 
2.5 years 
454 
pyrosequencing
318,620 16S rRNA 
gene sequences
Phylogenetic diversity correlates with 
age. Diversity changed gradually in 
four discrete phases: (1) days 1 to 92: 
Firmicute OTUs; (2) fever at day 92: 
proteobacterial and actinobacterial 
OTU abundances, suite of Firmicute 
OTUs differed; (3) exclusion of breast 
milk; and (4) introduction of peas and 
cefdinir use: increase in Bacteroidetes
Carbohydrate metabolism; amylose, arabinose 
and maltose degradation; virulence genes 
enriched; rhamnose, fructo-oligosaccahride 
and raffinose-utilization pathways, and xylose-
degradation genes expressed; lactose/galactose 
and sucrose utilization; antibiotic resistance; 
vitamin biosynthesis; sialic acid metabolism, 
β-glucoronide utilization; polysaccharide 
metabolism (day 371: maltose, maltodextrin, 
xylose); xenobiotic degradation; benzoate 
catabolism and aromatic metabolism
Summary of the key experimental findings and the predominant phylogenetic data, and specific pathways and functional pathways highlighted by analysis from the 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and clusters of orthologous groups (COG) analysis. CAZy, carbohydrate-active enzyme; DZ, dizygotic; 
DXP, deoxyxylulose 5-phosphate; IPP, isopenteryl pyrophosphate; MEP, 2-methyl-d-erythritol 4-phosphate; MZ, monozygotic; OUT, operational taxonomic unit. 
Applied Biosystems, Carlsbad, CA, USA; GE Healthcare, Piscataway, NJ, USA; Illumina, San Diego, CA, USA.
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proteomic or metabolic level), meaning that other tools 
may be required for its further analysis. It also suggests 
that from a systems perspective we are highly variable 
with tremendous implications for personalized health-
care strategies. A key question now is: how is this unique 
ecosystem assembled and maintained within individuals 
or across species?
Initial metagenomic analysis seems to confirm the sta-
bility of some microbial species between animal species. 
Fecal DNA samples from dogs were analyzed using 454 
pyrosequencing [40]. Sequenced data were interpreted by 
the Meta Genome Rapid Annotation using Subsystem 
Technology (MG-RAST [41]) and this was compared 
with paired data from lean and obese mouse cecal meta-
genomes [7] and two human fecal metagenomes (F1S; 
HSM) [37]. The Bacteroidetes/Chlorobi and Firmicutes 
phyla comprised 35% of all sequences, followed by 
Proteobacteria (13% to 15%) and Fusobacterium (7% to 
8%). Hierarchical clustering of several gastrointestinal 
meta genomes demonstrated phylogenetic and metabolic 
similarity between dogs, humans and mice.
Metagenomic approaches are not just restricted to the 
analysis of microbial genomes. A more novel area of work 
relates to the analysis of the interaction of the gut 
microbiome with gut parasites, viruses, yeasts and fungi, 
and its importance for human health [42]. Fungal inter-
actions with the distal gut microbiome have yet to be 
characterized using a metagenomic analysis, although 
this has been attempted within the oral microbiome 
using a multitag pyrosequencing approach in 20 healthy 
individuals [43]. However, the gut virome has recently 
been investigated. Fecal samples were collected from 
healthy adult female monozygotic twins and their mothers 
at three time points over a 1-year period [44]. These 
datasets were compared with datasets of sequenced 
bacterial 16S rRNA genes and total-fecal-community 
DNA. In keeping with other studies reported in the 
literature, twins and their mothers share a significantly 
greater degree of similarity in their fecal bacterial 
communities when compared with unrelated individuals. 
However, viromes were found to be unique to individuals 
regardless of their degree of genetic relatedness. Further-
more, intrapersonal diversity was very low, with 95% of 
virotypes retained over the period surveyed. These 
results suggested that the viral-microbial dynamic found 
in other environmental ecosystems was not present in 
the very distal intestine. This area of research is likely to 
become increasingly important as more of the interking-
dom signaling pathways are elucidated, and the impor-
tance of viral, parasite and fungal mutualism is recog-
nized. Metagenomics therefore represents a growing and 
important area of research into the gut microbiome, and 
work in this area continues to generate new, potentially 
important taxa that are being described [45].
The functional role of the gut microbiome in 
health, disease and drug efficacy
Culture-independent genomic strategies are not without 
limitations because of their inability to infer organismal 
function from these gene sequences. A genomic strategy 
will therefore largely only describe the potential for a 
disease state. Hybrid approaches are thus required to 
provide temporal information about the actual biological 
activity of the microbiome. Approaches such as proteo-
mics and metabonomics can thus be used to study the 
functional capacity of the gut microbiome from the top 
down [46,47]. Real time analysis of the intestinal micro-
biome is essential for both the development and the 
monitor ing of interventional personalized therapeutic 
strategies. Metabonomics describes the computational 
analysis of spectral metabolic data to provide information 
on time-specific metabolic changes across a complex 
system [48]. In turn, this has led to the concept of ‘global 
metabolic profiling’, which provides a unique overview of 
the metabolic state of an individual. This is because it is 
able to indirectly measure complex transgenomic co-
metabolic interactions that are vital for human health, 
and which are often modulated by disease [49,50]. The 
notion of microbial-mammalian metabolic cooperation is 
defined through the concept of the human metabonome 
(the sums and interactions of all the cellular metabo-
lomes) [51]. Metabolic profiling coupled with the meta-
genomic study of the gut microbiota permits the close 
inter-relationship between the host and microbial 
‘metabotypes’ to be studied in great detail, and provides 
the basis for further understanding the microbial-mam-
malian metabolic axis. Ultimately, this has led to the idea 
of ‘functional metagenomics’, defined as ‘the characteri-
zation of key functional members of the microbiome that 
most influence host metabolism and hence health’ [52].
Metabolic profiling strategies, such as high-throughput 
analysis by NMR spectroscopy or mass spectrometry, are 
widely used to provide global metabolic overviews of 
human metabolism [8,47,48,53-55]. These methods are 
used in conjunction with computational multivariate 
analysis to provide a deeper understanding of disease 
states and biomarker discovery. This approach allows the 
quantification of environmental influences on the host 
genome and human health [48,55]. This analytical 
strategy has now been successfully applied to disease 
states such as hypertension [8], ischemic heart disease 
[56], diabetes [57] and obesity [58] as part of large-scale 
clinical studies. These studies suggest that the intestinal 
microbiome is essential in determining the metabolic 
response of the host to environmental stimuli and thus 
disease. Moreover, the intestinal microbiome is essential 
for determining the toxic response to pharmacological 
therapies, and the case of paracetamol permits pre-dose 
predictions of toxicity to be made [18,59].
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The systematic characterization of the metabolic content 
of aqueous fecal extracts across humans, mice and rats 
has been performed using high-resolution NMR spectro-
scopy [60]. Although many fecal metabolites are common 
to the three species, such as short-chain fatty acids 
(SCFAs) and branched chain amino acids, each host 
species generates a unique metabolic profile when 
analyzed by multivariate analysis. This analysis refers to a 
suite of unsupervised (for example, principal component 
analysis) or supervised methods (for example, partial 
least squares discriminant analysis) for analyzing large-
scale spectroscopic data sets.
The biochemical composition of intact intestinal tissues 
(duodenum, jejunum, ileum, and proximal and distal 
colon) has recently been studied in germ-free mice 
inocu lated with human baby microbiota, using magic-
angle-spinning NMR spectroscopy. The HBF-inoculated 
tissue metabolite profiles were then compared with those 
from conventional (that is, gnotobiotic mice transfected 
with normal mouse intestinal flora) and conventionalized 
mice (gnotobiotic mice transfected with HBF). This 
demon strated that biochemical topographical variation 
exists between intestinal regions that are specific for the 
microbiomes. In particular, osmolytes were affected and 
the duodenum had higher ethanolamine and myo-
inositol quantities, and the ileum had higher taurine and 
betaine levels than other gut regions. HBF mice showed 
lower taurine and myo-inositol levels in the colon, and all 
ex-germfree animals had higher taurine, choline and 
ethano lamine levels in the jejunum. Interestingly, the 
jejunum of HBF mice was marked by a higher glutathione 
level and lower concentrations of its precursor methio-
nine when compared with other groups [61].
Top-down multivariate analysis of metabolic profiles 
also reveals a significant association of specific metabo-
types with the resident microbiome. Martin et al. [62] 
derived a transgenomic graph model showing that HBF 
has a remarkably simple microbiome/metabolome corre-
la tion network, impacting directly on the ability of the 
host to metabolize lipids, and fundamentally altering the 
biliary enterohepatic circulation. This effect can also be 
measured in plasma using an approach based on mass 
spectrometry [54]. The production of indole-3-propionic 
acid was shown to be completely dependent on the 
presence of gut microflora, and could be established by 
colonization with the bacterium Clostridium sporogenes. 
Multiple organic acids containing phenyl groups were 
also greatly increased in the presence of gut microbes. 
More interestingly, a broad, phase II metabolic response 
of the host to metabolites generated by the microbiome 
was observed, suggesting that the gut microflora have a 
direct impact on drug metabolism.
This variation between individuals continues at a pro-
teomic level. A non-targeted, shotgun mass-spectro-
metry-based whole community proteomics, or meta-
proteo mics, approach has been used for measurements 
of thousands of proteins in human fecal samples taken 
from two monozygotic twins. Analysis was performed 
using two-dimensional liquid chromato graphy-mass 
spectrometry/mass spectrometry [47]. In contrast to 
metagenomic data sets, the metaproteome had relatively 
more of its distribution attributed to translation, energy 
production and carbohydrate metabolism. Antimicrobial 
peptides were also identified, suggesting that the mam-
malian response to the gut microbiome can also be quan-
tified. Several unknown proteins were also described for 
microbial pathways or host immune responses, revealing 
a novel complex interplay between the human host and 
its associated microbes. However, a significant problem 
arises with proteomic analysis, and this is that the 
number of unknown proteins far outweighs the number 
of unknown genes. This is likely to serve as a significant 
bottleneck in the functional use of proteomic data for use 
in future analysis of the gut microbiome.
The effect of the gut microbiota on drug metabolism 
has been previously explored, and the metabolic pathway 
of several drugs, such as l-DOPA, sulfasalazine, digoxin 
and even glyceryl trinitrate, has been established in the 
gut [63]. However, metabonomic approaches are creating 
new insights into commonly prescribed drugs, such as 
simvastatin, that were not previously appreciated. This is 
the most commonly prescribed statin in a billion dollar 
global market. It serves as an inhibitor of 3-hydroxy-3-
methylglutaryl coenzyme A, regulating hepatic choles-
terol production. Simvastatin is degraded in the gut by 
hydrolytic cleavage of methylbutanoic acid from its 
backbone. Metabolism involves gut microbial processes 
of the demethylation of dimethylbutanoic acid, hydroxy-
lation/dehydroxylation and β-oxidation, resulting in the 
production of 2-hydroxyisovaleric acid (3-methyl-2-
hydroxy butanoic acid), 3-hydroxybutanoic acid and lactic 
acid (2-hydroxypropanoic acid), and finally re-cyclization 
of heptanoic acid to produce cyclohexanecarboxylic acid 
[64]. The implication is significant, as there may be much 
greater variability of statin drug metabolism between 
individuals than is currently appreciated, and this serves 
as an example for the need for better personalized 
approaches to drug development.
Several disease states are now being linked with patho-
logical variation in the gut microbiome using functional 
approaches such as metabonomics or proteomics and 
metagenome level analysis.
An exploration of the dominant bacteria in patients 
with colorectal cancer (CRC) was recently undertaken 
[65]. A significantly reduced temporal stability and in-
creased diversity for the microbiota of subjects with CRC 
and polyposis was found using a 16S rDNA DGGE 
analysis. A significantly increased diversity of the 
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Clostridium leptum and Clostridium coccoides subgroups 
was also noted for both disease groups. A clear division 
in the metabonome was observed for the CRC and 
polypectomized subjects compared with control volun-
teers. The production of hydrogen sulfide, an end product 
of metabolism by the sulfate-reducing bacteria, has been 
cited as a potential etiological agent in gastrointestinal 
disease. Hydrogen sulfide has genotoxic, cytotoxic and 
inflammatory effects, and its inefficient metabolism by 
species of sulfate-reducing bacteria could have a critical 
impact on the health of the host. Therefore, in a separate 
study, the same authors used quantitative PCR to study a 
cohort of CRC and polypectomized patients. CRC 
patients had significantly lower numbers of Desulfovibrio 
species than healthy individuals, suggesting a possible 
new role for the gut bacteria in the mechanism of CRC.
Bacterial genes involved in regulation of NF-κB signaling 
in intestinal epithelial cells have been described recently 
using a HT-29 cell line, transfected with a plasmid 
containing the secreted alkaline phosphatase gene under 
the control of NF-κB binding elements [66]. Screening of 
2,640 metagenomic clones led to the identi fication of 171 
modulating clones and, among these, one stimulatory 
metagenomic clone, 52B7, was sequenced. This suggested 
that the metagenomic DNA insert might belong to a new 
Bacteroides strain, and two loci encoding an ATP-binding 
cassette transport system and a putative lipoprotein are 
potentially involved in the 52B7 effect on NF-κB.
The gut microbiome has been extensively linked with 
IBD, and recently the ‘hygiene hypothesis’ has been 
implicated; this suggests that a reduction in microbial 
exposure as a result of improved health measures has 
contributed to an immunological imbalance in the intes-
tine, and has increased the incidence of autoimmune 
diseases such as IBDs [67]. Culture-independent tech-
niques are also providing new information on the gut 
ecology of these conditions. Specific bacterial popula-
tions are activated in patients with IBD, while other 
groups are in an inactive or ‘dormant’ state, such as the 
Actinobacteria and Firmicutes, while Escherichia species 
have been found to be both abundant and active in the 
Crohn’s disease and ulcerative colitis groups [68]. Pseudo-
monas species are also less diverse in Crohn’s disease 
patients compared with non-IBD patients. In particular 
Pseudomonas aeruginosa was only identified in non-IBD 
patients [69]. Irrespective, there is increasing evidence 
that the microbiome is able to directly influence the 
expression of the innate immune system via the Toll-like 
receptor (TLR) pathway [70]. Commensal bacteria are 
also vital for modulating the immune response, and 
SCFAs appear to be central to this process. New mecha-
nisms of action for these important metabolites are being 
found; for example, SCFAs bind to the G-coupled-
protein-receptor 43 and this is necessary for the 
resolution of certain inflammatory responses [71]. The 
hygiene hypothesis has therefore also been implicated in 
the etiology of asthma and atopy via a mechanism similar 
to that of the modulation of the innate immune response 
[72,73] (Figure 1).
The concept that intestinal microbial composition 
affects the health of the gut, and also influences centrally 
mediated systems involved in mood and mental health, is 
being increasingly reported. This is described by the gut-
brain communication hypothesis, and it is possible that 
the gut microbiota have a role in the pathogenesis of 
psychiatric disorders such as depression, particularly 
when linked to conditions such as IBD [74]. Animal 
studies have provided evidence to suggest a modulating 
role for probiotic bacteria in immune, neuroendocrine 
and neurochemical responses outside the gastrointestinal 
tract [75]. Specifically, the absence of gastrointestinal 
microbes in mice results in reduced production of brain-
derived neurotrophic factor in the cortex and hippo-
campus, and an exaggerated hypothalamic-pituitary-
adrenal axis response to stress [76]. A particularly 
interesting avenue of research has focused on the 
potential role of the gut microbiota in the mechanism of 
autism. Clostridium bolteae is significantly more preva-
lent in the gut of autistic children [77], and although the 
mechanism by which gut flora are able to initiate autism 
is as yet not elucidated, it has been hypothesized that this 
pathway may be of importance [10].
Gut microbiome ‘transplantation’
Previous studies have confirmed that transplanted micro-
biota may be able to maintain their ecological stability in 
the host animal for 6 months [78] to 1 year [79]. This 
suggests that these models are robust enough to study 
the mechanism of human diseases, at least in the acute 
phase, although it is not yet known if this approach 
accurately reflects the importance of the gut microbiota 
to human health over a period of ‘years’. However, short- 
to medium-term stability means that the metabolic 
potential of the gut microbiome can be harnessed for 
beneficial purposes, such as the treatment of antibiotic-
associated diarrhea. However, this approach does not 
always generate a positive outcome for the host. Such an 
effect was first reported by Turnbaugh et al. [7], who 
demon strated that the obesity phenotype was trans-
ferable after feces from obese mice were transferred to 
lean animals. Moreover, the same altered microbiome 
was demonstrated in a human study of obesity in lean 
and obese twins [29]. The transfer of cholesterol metabo-
lism characteristics has also been demonstrated in germ-
free rats. Gerard et al. [80] studied two groups of six, 
initially germ-free, rats associated with two groups of 
different human microbiota, which exhibited high and 
low cholesterol-reducing activities. Four months after 
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inoculation, the rats harbored a raised coprostanoligenic 
bacterial population level and exhibited coprostanoligenic 
activities similar to those of the corresponding 
human donor.
Deep sequencing and phylogenetic clustering has been 
used to examine the long-term effects of exogenous 
micro biota transplantation combined with and without 
an antibiotic pretreatment [81]. As a result of transplan-
tation, the intestinal bacterial diversity exceeded that of 
the human gut by a factor of two to three because of the 
capture of new phylotypes and an increase in abundance 
of others. However, antibiotic dosing prior to transplan-
ta tion does not increase the establishment of the donor 
phylotypes, although some dominant lineages still trans-
ferred successfully. These effects were observed after 
1 month of treatment, and persisted after 3 months. The 
authors concluded the gut microbial ‘plasticity’ is con-
ditioned by the altered microbiome and that altered gut 
homeostasis was caused by antibiotic pretreatment 
rather than by the primary bacterial loss. This is corro-
borated by top-down systems metabolism approaches, 
which suggest a significant effect of antibiotics on host 
metabolism. Female mice dosed with oral vancomycin, 
and characterized using NMR spectroscopy of urine and 
fecal extract samples [82], demonstrated a higher fecal 
excretion of uracil, amino acids and SCFAs, highlighting 
the contribution of the gut microbiota to the production 
and metabolism of these dietary compounds. Compari-
son of urinary hippurate and phenylacetylglycine concen-
tra tions to the fecal metabolite profile revealed a strong 
association between these urinary metabolites and a wide 
range of fecal metabolites, suggesting a causal link 
between antibiotic use and an altered metabonome [83].
However, gut microbial modulation is not always 
initiated by medical intervention, and small bowel trans-
plants used in cases of intestinal failure permit an oppor-
tunity for long-term study of the microbial ecology of the 
human small bowel. This is because an ileostomy is 
created during surgery for monitoring the progress of the 
allograft and this provides access to samples of ileal 
effluent and mucosal biopsies. Seventeen patients with 
small bowel transplants were recently studied over a 
period of 8 weeks and they had their ileal content 
measured by quantitative PCR [52]. This demonstrated a 
form of microbial ‘metaplasia’, where the normally strict 
anaerobic Bacteroides and Clostridium species were 
replaced by Lactobacillus and Enterobacteriacae, which 
are typically facultative anaerobes. After surgical closure of 
the ileostomy, the community reverted to the normal 
structure. Metabonomic profiling demonstrated enrich-
ment for metabolites associated with aerobic respiration in 
samples from patients with open ileostomies, supporting 
the hypothesis that oxygen exposure was responsible for 
the change [53].
Therapeutic implications of gut microbiome 
modulation
The potential therapeutic role of the gut microbiota for 
human health has led to therapeutic approaches such as 
bacteriotherapy [83] and bioecological control [84]. 
Broadly, these theories argue that modulation of intes-
tinal floral populations either by the pre-morbid gut 
microbiota of the host or by prebiotics, probiotics and 
synbiotics may be beneficial for human health [85]. 
Several studies now suggest that fecal transplantation 
may be beneficial in states of antibiotic-associated diar-
rhea or Clostridium difficile infection [86-88]. However, 
the long-term functional or metabolic consequences for 
the host of microbial modulation are poorly understood. 
New insights are being provided through the analysis of 
probiotic and prebiotic studies using global metabolic 
profiling techniques, where evidence suggests that the 
effect may be cumulative [45,89]. The effects of the 
probiotics Lactobacillus paracasei or Lactobacillus rham-
nosus, and two galactosyl-oligosaccharide prebiotics, 
were studied in germ-free mice inoculated with HBF. 
When the therapies were combined, populations of 
Bifidobacterium longum and Bifidobacterium breve 
increased, and Clostridium perfringens decreased. These 
microbial effects were associated with modulation of a 
range of host metabolic pathways indicated by changes in 
lipid profiles, gluconeogenesis, and amino acid and 
methylamine metabolism, and were associated with fer-
men tation of carbohydrates by different bacterial strains. 
Hierarchical-principal component analysis also permit-
ted the visualization of multicompartmental trans-
genomic metabolic interactions that were also resolved at 
the compartment and pathway level. More novel 
approaches that incorporate parasites that interact with 
the gut microbiome have also been suggested, such as the 
use of helminths in IBD [90].
Probiotic therapies have now been proposed for a large 
variety of gut-related disorders such as IBD, inflammatory 
bowel syndrome and pouchitis after surgery for IBD. 
However, there are more novel areas of potential appli-
cation. A recent study assessed the potential benefits of 
the probiotic Bifidobacterium infantis in the rat maternal 
separation model [91]. Maternal separation adult rat 
offspring were chronically treated with bifido bacteria or 
citalopram and subjected to the forced swim test to 
assess motivational state. Probiotic treatment resulted in 
normalization of the immune response, reversal of 
behavioral deficits after maternal separation and a forced 
swim test, and restoration of basal nor adrenaline concen-
trations in the brainstem.
It is highly likely that more detailed information on the 
ecology of the gut will lead to more medical targets for 
colonic and systemic disease states. The first evidence of 
this approach is now emerging, as drugs may also be 
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designed to inhibit undesirable enzyme activities in 
essential microbial symbiotes to enhance chemothera-
peutic efficacy. Recently, a novel approach has been 
described through bacterial modulation of the dose-
limiting side effect of the common colon cancer chemo-
therapeutic CPT-11. This commonly causes severe 
diarrhea by reactivation of the symbiotic bacterial β-
glucuronidases in the gut. Potent bacterial β-glucuroni-
dase inhibitors have been identified by high-throughput 
screening and been shown to have no effect on the 
orthologous mammalian enzyme [92]. Inhibitors were 
highly effective against the enzyme target in living 
aerobic and anaerobic bacteria, but did not kill the 
bacteria or harm mammalian cells and oral adminis tra-
tion of an inhibitor protected mice from CPT-11-induced 
toxicity. This suggests that the creation of personalized 
strategies for altering drug toxicity is readily achievable. 
This is corroborated by clinical trials showing that 
probiotics such as Bifidobacterium and Lactobacillus 
improve mood and reduce anxiety symptoms in patients 
with chronic fatigue syndrome and inflammatory bowel 
syndrome [76].
The concept of ‘personalized’ health care is therefore 
totally dependent on a better understanding of the gut 
microbiome from the top down and the bottom up 
[25,93]. Single probiotic agents are unlikely to dramati-
cally alter long-term health across populations without 
targeted interventions based on a prior knowledge of the 
microbial requirements of a specific person. This is even 
more important in the diseased gut, where the ecosystem 
may already be deleteriously affected. Even the effective 
delivery of engineered bacteria for the delivery of 
endogenous therapeutic agents, which has been proposed 
for conditions such as IBD [94], will be dependent on a 
predictable ecosystem.
Bariatric surgery aims to reduce the volume of the 
stomach and increase transit times of food by diverting 
the flow of small bowel effluent through a gastric bypass 
procedure. Recently, 184,094 sequences of microbial 16S 
rRNA genes from PCR amplicons were examined using 
the 454 pyrosequencing technology to compare the 
micro bial community structures of nine individuals: 
three in each of the categories of normal weight, morbidly 
obese, and post-gastric-bypass surgery [95]. Phylogenetic 
analysis demonstrated that although the bacteria in the 
human intestinal community were highly diverse, they 
fell mainly into six bacterial groups with distinctive 
divisions. Specifically, Firmicutes were dominant in 
normal-weight and obese individuals, but were 
significantly decreased in post-gastric-bypass individuals, 
who also had a proportional increase of Gammaproteo-
bacteria. Hydrogen-producing Prevotellaceae were highly 
enriched in the obese individuals. Unlike the highly 
diverse bacteria, the archaea comprised mainly members 
of the order Methanobacteriales, which are hydrogen-
oxidizing methanogens. Using real-time PCR, signifi-
cantly higher numbers of hydrogen-utilizing methano-
genic archaea were detected in obese individuals than in 
normal-weight or post-gastric-bypass individuals. The 
authors hypothesized that interspecies hydrogen transfer 
between bacterial and archaeal species is an important 
mechanism for increasing energy uptake by the large 
intestine in obese persons [95]. It is difficult to definitively 
ascertain whether the surgical trauma, the bypass or the 
altered oral intake is definitively responsible. Nonethe-
less, the inference is that it may be possible to medically 
alter the entire gut microbial make-up of obese patients 
for the purpose of altering energy metabolism and thus 
weight loss. More importantly, gastric bypass patients 
with type II diabetes mellitus are rapidly and definitively 
cured of this condition [96]. Modern bariatric procedures 
therefore represent ‘super system’ surgery that seeks to 
alter the microbiome as part of the surgical procedure for 
the benefit of human health. If the intestinal microbiota 
are involved in this mechanism in some way, and it is 
highly likely that they are, then the treatment of type 2 
diabetes mellitus by microbiotal modulation may repre-
sent an even more valuable drug target than surgery in 
the treatment of obesity.
Significantly, recent evidence suggests that mice geneti-
cally deficient in TLR5, a component of the innate 
immune system that is expressed in the gut mucosa and 
that helps defend against infection, exhibit hyperphagia 
and develop hallmark features of metabolic syndrome, 
including hyperlipidemia, hypertension, insulin resis tance 
and increased adiposity [97]. These metabolic changes 
correlated with changes in the composition of the gut 
micro biota, and transfer of the gut microbiota from TLR5-
deficient mice to wild-type germ-free mice con ferred 
many features of metabolic syndrome to the recipients, 
reciprocating work previously described by Turnbaugh et 
al. [7,98]. This suggests that the altered innate immune 
system may play a direct role in the method of microbial 
modulation of diabetes in the metabolic syndrome.
This theory is supported in part by metabonomic studies 
of obesity, because both lean and obese animals have 
specific metabolic phenotypes that are linked to their 
individual microbiomes. The two functionally and 
phenotypically normal Zucker rat strains (fa/- and -/-) 
were readily distinguished from the (fa/fa) obese rats on 
the basis of their metabotypes, with relatively lower levels 
of urinary hippurate and creatinine, relatively higher levels 
of urinary isoleucine, leucine and acetate, and higher 
plasma low-density lipoprotein and very low-density lipo-
protein levels typifying the (fa/fa) obese strain [99]. 
Therefore, if truly personalized strategies that deliver an 
improved quality of care to patients are ever to be delivered 
for globally important health problems such as obesity, 
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systems biology approaches that account for mammalian/
microbial mutualism at genomic, proteomic and metabolic 
levels are urgently required. These approaches will have an 
impact across medicine and surgery, and they will deliver 
the next generation of drug therapies.
Conclusions
Systems biology has irrevocably altered the view that 
mammalian metabolism is solely influenced by the 
human genome. A core gut microbiome may exist within 
the human gut, at least at a genomic or metabolic level, 
and this is fundamental to the maintenance of health, the 
development of disease and human metabolic processes. 
However, there is a large variation in the microbial 
content of the distal gut between individuals and popu-
lations, and it is sensitive to genomic, dietary, age, sex, 
pharmaceutical and even surgical interventions. Systems 
biology approaches at the metabonomic and proteomic 
level have greatly increased the potential of genomic 
strategies by providing a ‘functional’ analysis of gut 
microbial function, and this suggests that the biological 
mutualism is not only deeper than previously described, 
but it may also be modulated for the improvement of 
human health. Next-generation genomic technologies 
will lead to the development of experimental models that 
are more representative of the human gut microbiome 
for hypothesis testing. This, in turn, will expedite the 
discovery, testing and validation of novel drug targets. 
However, a rapid resolution of the bottleneck in the 
proteomic pipeline is now of the upmost importance if 
this vision is to be realized. Future metagenomic research 
is also likely to center on the complex relationships of the 
gut microbiome with the hundreds of other species of gut 
fungi, viruses, yeasts and parasites so that in time their 
true importance to human health will also be better 
understood. Computational modeling of the gut eco-
system at a systems level may yet permit advances in 
cellular engineering technologies that are able to utilize 
the microbiome for drug delivery, production and disease 
prevention targeted at the individual. But, even before 
this vision is realized, the gut microbiome will greatly 
contribute to the delivery of personalized healthcare 
strategies that are already being translated into the 
clinical environment for the benefit of patients.
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